China Clears For Market World's First H1N1 Flu Vaccine, By Sinovac
This article was originally published in PharmAsia News
China has given its clearance to the first locally mass-produced H1N1 flu vaccine to Sinovac Biotech. The final approval came after a panel of experts earlier in the week recommended both Sinovac and Hualan Biological Engineering be allowed to produce their versions. As the first, Sinovac's one-shot treatment is likely to be the first on the market, contributing enough dosages to treat 5 percent of the Chinese population by the end of the year. Sinovac was the first company globally to complete clinical trials on a vaccine. (Click here for more
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.